German pharmaceutical firm and vaccine maker BioNTech on Friday said it had agreed in principle to establish an mRNA manufacturing facility in Melbourne. The company said it would collaborate with government in the Australian state of Melbourne to collaborate “on the research and development of potential mRNA-based vaccines and therapies.” Messenger ribonucleic acid (mRNA) technology has already been employed successfully in BioNTech’s coronavirus vaccine. “BioNTech plans to set up a clinical scale end-to-end mRNA manufacturing facility based on its BioNTainer solution in Melbourne with the ai…